Literature DB >> 88710

Drugs or drums: what relieves postoperative pain?

M Keeri-Szanto.   

Abstract

The cybernetic model of analgesia is a simple servo-loop: altered sensory input--complaints--medication--temporary restoration of acceptable processing of the sensory input--return of altered sensations. Under ordinary clinical circumstances the functioning of this mechanism is masked by "noise" generated by the interaction of several persons who provide the medication and time factors prolonging the interval between the onset of complaints and the action of the medication. Demand analgesia (DA) has been designed to provide prompt pain relief under the patient's direct control. The technique turned out to be useful also for the investigation of acute pain's course. The present protocol was designed to study the precision with which patients respond to minute changes in the level of a narcotic (hydromorphone) at the target site: this was achieved by varying in a double-blind fashion the amount of narcotic delivered in response to triggering the apparatus and noting how the patient adapts the dosing interval in response to the imposed changes. Thirty-four patients were studied following extensive surgery. Observation times ranged from 16 to 75 h (median 45 h) during which 89 dose changes were initiated. While the majority of subjects adapted successfully to up to 4-fold variations in drug delivery, a sizeable minority (7/34) triggered the apparatus in response to some clue other than the amount of drug received. These non-drug responders seem to correspond to the "placebo reactors" of other therapeutic settings. Our calculations allowed the estimation of how large was the contribution of drug action and non-drug action to the overall therapeutic effect. In the drug-responsive group, the mean contribution of drug action was 78%, while among the non-drug responders this amounted to only 40%. The difference between these two figures is statistically significant (P less than 0.02), at the same time it also reveals important contributions of non-drug factors in drug responders and vice versa. Whether a subject behaves as a placebo reactor or not might depend on the circumstances rather than on innate mechanisms.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 88710     DOI: 10.1016/0304-3959(79)90129-5

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  8 in total

Review 1.  Treatment principles for the use of opioids in pain of nonmalignant origin.

Authors:  S A Schug; A F Merry; R H Acland
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Patient-controlled analgesia with nalbuphine, a new narcotic agonist-antagonist, for the treatment of postoperative pain.

Authors:  K A Lehmann; B Tenbuhs
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Patient-controlled analgesic therapy, Part II: Individual analgesic demand and analgesic plasma concentrations of pethidine in postoperative pain.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

4.  Comparison of epidural and patient-controlled intravenous morphine following joint replacement surgery.

Authors:  R Weller; M Rosenblum; P Conard; J B Gross
Journal:  Can J Anaesth       Date:  1991-07       Impact factor: 5.063

Review 5.  Patient-controlled analgesia. Pharmacokinetic and therapeutic considerations.

Authors:  H F Hill; L E Mather
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

6.  [Postoperative on-demand analgesia with pentazocine (Fortral)].

Authors:  K A Lehmann; B Tenbuhs; W Hoeckle
Journal:  Langenbecks Arch Chir       Date:  1985

Review 7.  Optimum management of postoperative pain.

Authors:  R E Bullingham
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

8.  "Anxiebo", placebo, and postoperative pain.

Authors:  Paul Svedman; Martin Ingvar; Torsten Gordh
Journal:  BMC Anesthesiol       Date:  2005-06-27       Impact factor: 2.217

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.